ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with brain metastases

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

5 year follow-up

When the history of ADC is written: Redefining first-line standard of care in mUC!

Early use of enzalutamide in advanced prostate cancer

Clearing up non-clear cell RCC

Lu-PSMA leads forward

New 3rd line therapy for RCC

The FGFR story in bladder cancer at ESMO23

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Tarlatamab in SCLC

ALINA - immediate change of practice!

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

What was the most exciting news at ESMO23?

New and better biomarkers are needed!

What is your definition of triple-negative breast cancer?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

Anticipated updates and exciting new data for checkpointinhibitors

Immunoncology in eBC - triple negative and more?

Negative EFS results from NeoTrip

Carry-over effects in monarchE confirmed

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Clinically relevant effect of pembro also in PCR

ER-low corresponds diagnostically to ER-0 breast cancer

Analysis of tumour microenvironment and immunophenotype in TNBC

Detailed view of nodal-negative patients

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

MonarchE - trial update

New data on neoadjuvant immunotherapy

5 year follow-up

HR+ study with > 20 % PCR

Consolidation of data in early HR+ and triple-negative breast cancer

Our guidelines are correct

Highlights in eBC

Preoperative checkpointinihition in ER+ disease

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Pembrolizumab solidifies as SOC in early-stage TNBC

My highlights of ESMO23 in early breast cancer

Ribociclib effective in all subtypes

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Nouvelles données sur l'immunothérapie néoadjuvante

Studio NeoTrip: negativi i risultati

Punti salienti in eBC

MonarchE - mise à jour de l'essai

How to organize a molecular tumorboards in breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

New ADC for metastatic breast cancer?

What was the most exciting news at ESMO23?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

OP seems to be dispensable for super responders

HS20089 - a novel ADC is coming for TNBC

T-DXd - new standard of care for brain mets?

Patient-centered molecular medicine - a new approach

Dato-DXd - new player in advanced luminal disease

Highlights in mBC

Duvalumab + Dato-DXd effective

HER2DX in the PHERgain trial

TROP2 expression as a potential mechanism of resistance in HER2+ patients

Abemaciclib remains consistent in 5-year follow-up

New ADC in HR+ disease

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Robust data from the monarchE

T-DXd also effective for brain metastases

Can surgery be spared following primary systemic therapy?

T-DXd in HER2+ patients with brain metastases

DATO-DX - where is it going?

ADC + Immunotherapy - the BEGONIA study paradigm

Our guidelines are correct

Still on track for success in HER2-low MBC

TULIP: Trastuzumab duocarmazine without OS benefit

My highlights of ESMO23 in metastatic breast cancer

Fulvestran better than anastrozole, but no survival benefit

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Improved oncological therapy with the smartphone

Benefit for SG even after intensive pretreatment

Even more new generation ADCs in breast cancer?

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

HER2DX en el estudio PHERgain

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Lo studio BEGONIA nelle paziento con tumore triplo negativo

Punti salienti in mBC

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

What is the future of immune therapy in prostate cancer?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust data is needed.

Osteoprotection at mHSPC

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Salvage radiotherapy the new standard

TITAN: ultra-low PSA = best prognosis

Embark without fear

Combination of radioligand therapy with chemotherapy useful

Immunotherapy in metastatic PCa

CXCR2 inhibitor in PCa

Big data and AI prediction tools

Negative data for pembrolizumab in mHSCPC & mCRPC

PSMAfore unleashes urooncologic opportunity

EMBARK - Quality of Life

Lu-PSMA leads forward

IO therapy in metastatic prostate cancer.

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Longterm toxicity of adjuvant RT after prostatectomy

Brave New World in mCRPC

Early use of enzalutamide in advanced prostate cancer

Precision medicine at mCRCP

PSMA FORE: Trial and controversies

RADICALS RT: Trial and controversies

EMBARK expands ENZA indication to PCa

ENZA P:Trial and controversies

STAMPEDE data. Skelettstärkande och riskstratifiering.

Big Data och AI för prediktion vid prostatacancer

Immunterapi vid prostatacancer

CXCR2 hämmare och prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

EMBARK och livskvalitet

Part1: New standard of care in first line urothelial cancer?!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Chemo-IO establishes itself in the first-line treatment of bladder cancer

New SoC in firstline bladder cancer

Amazing new data in bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

EV + Pembro as standard of care in first-line therapy of bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

DAD, DAD-IO

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Is de-escalating therapy ready for prime-time?

Where does the future therapy go in renal cell carcinoma?

Important new treatment option but only for subset of patients?

Kidney cancer highlights at ESMO23

New mode of action in mRCC - ready for prime time?

Clearing up non-clear cell RCC

Intermittent therapy also possible with TKIs

Belzutifan in later lines of therapy

Belzutifan - whats next kidney cancer?

New 3rd line therapy for RCC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

ALINA - immediate change of practice!

Perioperative IO: OS-benefi from KEYNOTE-671

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Big improvements in early stage and a subset of metatstic NSCLC

Circulating DNA in AEGEAN trial

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Substantial improvement in local regional NSCLC

Scene is set for inductive immunotherapy

ALINA - a new paradigm in operated NSCLC with ALK-fusion

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Les points forts de l'ESMO 2023

I miei punti salienti di ESMO 2023

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Activating EGFR-mutation - what's coming up?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

TROPION-Lung01: positive development

Treatment sequences for EGFR-mutated Patients

By unanimous decision and still the champion – docetaxel!

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Substantial improvement in rare alterations

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

NRG fusions: a new drugable target?

Amivantamab at progression? MARIPOSA-2 trial

My highlights from ESMO 2023

Changing treatment landscape in EGFR-mutated NSCLC

Practice changing results on exon 20 insertion mNSCLC

MARIPOSA II: Trial and controversies

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Do ADCs have brain activity?

Amivantamab upfront? MARIPOSA trial

MARIPOSA: Trial and controversies

LIBRETO - a positive study, but was it necessary?

PAPILLON - bringing together therapy for the 1st line

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Brain metastases – options to improve the systemic treatment

Big improvements in early stage and a subset of metatstic NSCLC

Does immunotherapy still have a place in EGFR-positive mNSCLC?

Amivantamab at progression? MARIPOSA-2 trial

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Amivantamab upfront? MARIPOSA trial

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Quelles séquences thérapeutiques pour les patients EGFR mutés

Les points forts de l'ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

I miei punti salienti di ESMO 2023

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Impact of T-cell engagers in SCLC

Tarlatamab in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Neue Hoffnung für Patienten mit SCLC

Update on gynaecological cancers

Evolution of the revolution - the RUBY trial

New data on sarkomas

Precision oncology in CUP

New data on H&N Cancer

First data on luveltamab in multiline treatment for endometrial cancer

PCO Therapeutics